Raymond L Benza

List of Publications by Citations

179 papers	12,332 citations	50 h-index	109 g-index
234 ext. papers	14,516 ext. citations	3.9 avg, IF	5.85 L-index

#	Paper	IF	Citations
179	Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). *Circulation*, **2010**, 122, 164-72	16.7	1079
178	The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. *Circulation* , **2003**, 107, 1359-65	16.7	869
177	Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. *JAMA - Journal of the American Medical Association*, **2002**, 287, 1541-7	27.4	848
176	Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. *Chest*, **2010**, 137, 376-87	5.3	798
175	An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. *Chest*, **2012**, 142, 448-456	5.3	726
174	Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. *JAMA - Journal of the American Medical Association*, **2004**, 291, 1963-71	27.4	511
173	Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. *Journal of the American College of Cardiology*, **2003**, 41, 997-1003	15.1	401
172	Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. *Journal of the American College of Cardiology*, **2010**, 55, 1915-22	15.1	381
171	Pulmonary arterial hypertension: epidemiology and registries. *Journal of the American College of Cardiology*, **2013**, 62, D51-9	15.1	338
170	The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. *Chest*, **2012**, 141, 354-362	5.3	329
169	Five-Year outcomes of patients enrolled in the REVEAL Registry. *Chest*, **2015**, 148, 1043-54	5.3	263
168	Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. *Chest*, **2006**, 129, 683-8	5.3	242
167	The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. *Chest*, **2011**, 139, 128-37	5.3	231
166	Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. *Chest*, **2019**, 156, 323-337	5.3	201
165	Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. *Journal of the American College of Cardiology*, **2002**, 40, 970-5	15.1	196
164	Interventional and surgical modalities of treatment in pulmonary hypertension. *Journal of the American College of Cardiology*, **2009**, 54, S67-S77	15.1	191
163	Clinical risk factors for portopulmonary hypertension. *Hepatology*, **2008**, 48, 196-203	11.2	189

162	Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2005**, 172, 1586-9	10.2	183
161	Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. *American Journal of Respiratory and Critical Care Medicine*, **2009**, 179, 835-42	10.2	170
160	World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult--a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. *Journal of Heart and Lung Transplantation* , **2012**, 31, 913-33	5.8	165
159	Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension. *Journal of the American College of Cardiology*, **2008**, 52, 1683-92	15.1	142
158	Infection in ventricular assist devices: prevention and treatment. *Annals of Thoracic Surgery*, **2003**, 75, S48-57	2.7	112
157	Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. *British Journal of Haematology*, **2010**, 149, 426-35	4.5	99
156	Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. *Chest*, **2014**, 146, 1494-1504	5.3	94
155	Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. *Journal of Heart and Lung Transplantation*, **2007**, 26, 584-92	5.8	93
154	Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. *Journal of Heart and Lung Transplantation*, **2005**, 24, 2196-201	5.8	84
153	Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. *Chest*, **2008**, 134, 775-782	5.3	82
152	Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis. *Journal of Heart and Lung Transplantation*, **2015**, 34, 356-61	5.8	80
151	Late gadolinium enhancement in pulmonary hypertension predicts clinical events. *Journal of Cardiovascular Magnetic Resonance*, **2012**, 14,	6.9	78
150	Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. *European Respiratory Journal*, **2019**, 53,	13.6	75
149	Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. *Journal of Heart and Lung Transplantation*, **2015**, 34, 362-8	5.8	74
148	RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. *European Respiratory Journal*, **2017**, 50,	13.6	74
147	Palliation of allograft vasculopathy with transluminal angioplasty: a decade of experience. *Journal of the American College of Cardiology*, **2004**, 43, 1973-81	15.1	74
146	Infection during circulatory support with ventricular assist devices. *Annals of Thoracic Surgery*, **1999**, 68, 711-6	2.7	74
145	Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. *Journal of Heart and Lung Transplantation*, **2011**, 30, 1327-33	5.8	69

144	Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2015**, 191, 208-18	10.2	68
143	Validation of two predictive models for survival in pulmonary arterial hypertension. *European Respiratory Journal*, **2015**, 46, 152-64	13.6	62
142	Polyphenolics Increase t-PA and u-PA Gene Transcription in Cultured Human Endothelial Cells. *Alcoholism: Clinical and Experimental Research*, **2001**, 25, 155-162	3.7	62
141	Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. *Journal of Heart and Lung Transplantation*, **2011**, 30, 982-9	5.8	61
140	Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2015**, 192, 1345-54	10.2	60
139	Management of pulmonary arterial hypertension with a focus on combination therapies. *Journal of Heart and Lung Transplantation*, **2007**, 26, 437-46	5.8	59
138	Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. *Chest*, **2013**, 144, 1521-1529	5.3	58
137	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. *Lancet Respiratory Medicine,the*, **2019**, 7, 227-238	35.1	55
136	Analysis of the lung allocation score estimation of risk of death in patients with pulmonary arterial hypertension using data from the REVEAL Registry. *Transplantation*, **2010**, 90, 298-305	1.8	53
135	Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan. *Chest*, **2008**, 134, 139-45	5.3	51
134	Genetic testing in cardiovascular disease. *Journal of the American College of Cardiology*, **2007**, 50, 727-37	15.1	51
133	The impact of arrhythmias in acute heart failure. *Journal of Cardiac Failure*, **2004**, 10, 279-84	3.3	51
132	Significance of Residual Mitral Regurgitation After Continuous Flow Left□Ventricular Assist Device Implantation. *JACC: Heart Failure*, **2017**, 5, 81-88	7.9	50
131	Future perspectives for the treatment of pulmonary arterial hypertension. *Journal of the American College of Cardiology*, **2009**, 54, S108-S117	15.1	50
130	Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. *Journal of Heart and Lung Transplantation*, **2007**, 26, 63-9	5.8	49
129	Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective. *Journal of the American College of Cardiology*, **2011**, 57, 1053-61	15.1	48
128	Pulmonary hypertension related to left heart disease: insight from a wireless implantable hemodynamic monitor. *Journal of Heart and Lung Transplantation*, **2015**, 34, 329-37	5.8	47
127	Genotype-specific transcriptional regulation of PAI-1 expression by hypertriglyceridemic VLDL and Lp(a) in cultured human endothelial cells. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1997**, 17, 3215-23	9.4	47

126	Gene polymorphisms for plasminogen activator inhibitor-1/tissue plasminogen activator and development of allograft coronary artery disease. *Circulation*, **1998**, 98, 2248-54	16.7	46
125	Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease. *Chest*, **2006**, 129, 1009-15	5.3	44
124	Post-heart transplant diastolic dysfunction is a risk factor for mortality. *Journal of the American College of Cardiology*, **2007**, 50, 1064-9	15.1	40
123	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 1661-1670	10.2	38
122	Serotonin transporter polymorphisms in patients with portopulmonary hypertension. *Chest*, **2009**, 135, 1470-1475	5.3	34
121	Creation of a model comparing 6-minute walk test to metabolic equivalent in evaluating treatment effects in pulmonary arterial hypertension. *Journal of Heart and Lung Transplantation*, **2007**, 26, 732-8	5.8	34
120	Survival in pulmonary arterial hypertension patients awaiting lung transplantation. *Journal of Heart and Lung Transplantation*, **2013**, 32, 1179-86	5.8	33
119	Right ventricular pressure waveform and wave reflection analysis in patients with pulmonary arterial hypertension. *Chest*, **2007**, 132, 37-43	5.3	33
118	Cardiomyopathy in a carrier of Duchenne muscular dystrophy. *Journal of Heart and Lung Transplantation*, **2001**, 20, 781-4	5.8	33
117	Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. *European Respiratory Journal*, **2019**, 53,	13.6	32
116	A new Bayesian network-based risk stratification model for prediction of short-term and long-term LVAD mortality. *ASAIO Journal*, **2015**, 61, 313-23	3.6	32
115	Continuous hemodynamic monitoring in patients with pulmonary arterial hypertension. *Journal of Heart and Lung Transplantation*, **2008**, 27, 780-8	5.8	30
114	Imatinib in pulmonary arterial hypertension: c-Kit inhibition. *Pulmonary Circulation*, **2014**, 4, 452-5	2.7	29
113	Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension. *Chest*, **2021**, 159, 337-346	5.3	29
112	Association of Ambulatory Hemodynamic Monitoring of Heart Failure With Clinical Outcomes in a Concurrent Matched Cohort Analysis. *JAMA Cardiology*, **2019**, 4, 556-563	16.2	28
111	Endothelin antagonism and uric acid levels in pulmonary arterial hypertension: clinical associations. *Journal of Heart and Lung Transplantation*, **2014**, 33, 521-7	5.8	28
110	Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertension. *Journal of Heart and Lung Transplantation*, **2018**, 37, 365-375	5.8	27
109	One-year experience with intravenous treprostinil for pulmonary arterial hypertension. *Journal of Heart and Lung Transplantation*, **2013**, 32, 889-96	5.8	27

108	Meta-analysis of use of balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. *International Journal of Cardiology*, **2019**, 291, 134-139	3.2	26
107	Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension. *Cardiovascular Therapeutics*, **2013**, 31, 38-44	3.3	26
106	Genotype-specific transcriptional regulation of PAI-1 gene by insulin, hypertriglyceridemic VLDL, and Lp(a) in transfected, cultured human endothelial cells. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1998**, 18, 1803-9	9.4	26
105	A Bayesian Model to Predict Survival After Left Ventricular Assist Device Implantation. *JACC: Heart Failure*, **2018**, 6, 771-779	7.9	24
104	Thrombin decreases the urokinase receptor and surface-localized fibrinolysis in cultured endothelial cells. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1995**, 15, 410-9	9.4	24
103	Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry. *Chest*, **2018**, 154, 126-135	5.3	23
102	Treatment of end-stage heart disease with outpatient ventricular assist devices. *Annals of Thoracic Surgery*, **2002**, 73, 1489-93; discussion 1493-4	2.7	23
101	Use of Balloon Atrial Septostomy in Patients With Advanced Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. *Chest*, **2019**, 156, 53-63	5.3	22
100	REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. *Journal of Heart and Lung Transplantation*, **2018**, 37, 513-519	5.8	22
99	Limitations of right heart catheterization in the diagnosis and risk stratification of patients with pulmonary hypertension related to left heart disease: insights from a wireless pulmonary artery pressure monitoring system. *Journal of Heart and Lung Transplantation*, **2015**, 34, 438-47	5.8	21
98	Intrapulmonary shunting in primary pulmonary hypertension: an observation in two patients treated with epoprostenol sodium. *Chest*, **1998**, 114, 334-6	5.3	21
97	Pulmonary hypertension associated with sickle cell disease: pathophysiology and rationale for treatment. *Lung*, **2008**, 186, 247-254	2.9	20
96	Cardiac transplant patients response to the (31)P MRS stress test. *Journal of Heart and Lung Transplantation*, **2002**, 21, 522-9	5.8	20
95	Hypertriglyceridemic VLDL decreases plasminogen binding to endothelial cells and surface-localized fibrinolysis. *Biochemistry*, **1996**, 35, 6080-8	3.2	20
94	Sex-Based Differences in Left Ventricular Assist Device Utilization: Insights From the Nationwide Inpatient Sample 2004 to 2016. *Circulation: Heart Failure*, **2019**, 12, e006082	7.6	19
93	Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. *Journal of Heart and Lung Transplantation*, **2020**, 39, 300-309	5.8	19
92	The pathophysiology of endothelin in complications after solid organ transplantation: a potential novel therapeutic role for endothelin receptor antagonists. *Transplantation*, **2012**, 94, 885-93	1.8	19
91	Galactosidase A expressed in the salivary glands partially corrects organ biochemical deficits in the fabry mouse through endocrine trafficking. *Human Gene Therapy*, **2011**, 22, 293-301	4.8	17

90	Re-stenosis after drug-eluting stents in cardiac allograft vasculopathy. *Journal of Heart and Lung Transplantation*, **2008**, 27, 610-5	5.8	17
89	Expression of Plasminogen Activator Inhibitor Type I in Genotyped Human Endothelial Cell Cultures: Genotype-specific Regulation by Insulin. *Thrombosis and Haemostasis*, **1999**, 82, 1504-1509	7	17
88	Retrospective Validation of the REVEAL 2.0 Risk Score With the Australian and New Zealand Pulmonary Hypertension Registry Cohort. *Chest*, **2020**, 157, 162-172	5.3	17
87	Tissue Doppler assessment of longitudinal right and left ventricular strain and strain rate in pulmonary artery hypertension. *Echocardiography*, **2006**, 23, 872-9	1.5	16
86	Therapeutic angiogenesis: review of current concepts and future directions. *Journal of Heart and Lung Transplantation*, **2003**, 22, 370-82	5.8	16
85	Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study. *Journal of Heart and Lung Transplantation*, **2019**, 38, 43-50	5.8	16
84	Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. *Journal of Heart and Lung Transplantation*, **2018**, 37, 696-705	5.8	16
83	Ethanol-Induced Up-Regulation of the Urokinase Receptor In Cultured Human Endothelial Cells. *Alcoholism: Clinical and Experimental Research*, **2001**, 25, 163-170	3.7	15
82	Identification of a 251-bp Fragment of the PAI-1 Gene Promoter That Mediates the Ethanol-Induced Suppression of PAI-1 Expression. *Alcoholism: Clinical and Experimental Research*, **2001**, 25, 629-636	3.7	15
81	REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. *Journal of Heart and Lung Transplantation*, **2018**, 37, 836-843	5.8	14
80	Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, 166-174	10.2	14
79	Gene Polymorphisms for PAI-1 Are Associated with the Angiographic Extent of Coronary Artery Disease. *Journal of Thrombosis and Thrombolysis*, **1998**, 5, 143-150	5.1	14
78	MicroCT analysis of vascular morphometry: a comparison of right lung lobes in the SUGEN/hypoxic rat model of pulmonary arterial hypertension. *Pulmonary Circulation*, **2017**, 7, 522-530	2.7	13
77	Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. *Respiratory Medicine*, **2017**, 122 Suppl 1, S18-S22	4.6	13
76	Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes. *ClinicoEconomics and Outcomes Research*, **2017**, 9, 731-739	1.7	13
75	Monitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor. *Chest*, **2019**, 156, 1176-1186	5.3	13
74	Mid wall fibrosis on CMR with late gadolinium enhancement may predict prognosis for LVAD and transplantation risk in patients with newly diagnosed dilated cardiomyopathy-preliminary observations from a high-volume transplant centre. *ESC Heart Failure*, **2015**, 2, 150-159	3.7	13
73	TLR4 regulates pulmonary vascular homeostasis and remodeling via redox signaling. *Frontiers in Bioscience - Landmark*, **2016**, 21, 397-409	2.8	13

72	Three-dimensional micro computed tomography analysis of the lung vasculature and differential adipose proteomics in the Sugen/hypoxia rat model of pulmonary arterial hypertension. *Pulmonary Circulation*, **2016**, 6, 586-596	2.7	13
71	Low Accuracy of the HeartMate Risk Score for Predicting Mortality Using the INTERMACS Registry Data. *ASAIO Journal*, **2017**, 63, 251-256	3.6	12
70	Salvage peripheral extracorporeal membrane oxygenation using Cobe Revolution( ) centrifugal pump as a bridge to decision for acute refractory cardiogenic shock. *Journal of Cardiac Surgery*, **2012**, 27, 521-7	1.3	12
69	Harvest of pulmonary artery endothelial cells from patients undergoing right heart catheterization. *Journal of Heart and Lung Transplantation*, **2013**, 32, 746-9	5.8	12
68	Development of prognostic tools in pulmonary arterial hypertension: lessons from modern day registries. *Thrombosis and Haemostasis*, **2012**, 108, 1049-60	7	11
67	Transforming growth factor-beta polymorphisms and cardiac allograft rejection. *Journal of Heart and Lung Transplantation*, **2009**, 28, 1057-62	5.8	11
66	Relative perioperative bradycardia does not lead to adverse outcomes after cardiac transplantation. *American Journal of Transplantation*, **2003**, 3, 484-91	8.7	11
65	Is Anticoagulation Beneficial in Pulmonary Arterial Hypertension?. *Circulation: Cardiovascular Quality and Outcomes*, **2018**, 11, e004757	5.8	11
64	The Use of Risk Assessment Tools and Prognostic Scores in Managing Patients with Pulmonary Arterial Hypertension. *Current Hypertension Reports*, **2019**, 21, 45	4.7	10
63	A Novel Compound, "FA-1" Isolated from Prunus mume, Protects Human Bronchial Epithelial Cells and Keratinocytes from Cigarette Smoke Extract-Induced Damage. *Scientific Reports*, **2018**, 8, 11504	4.9	10
62	Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series. *Pulmonary Circulation*, **2017**, 7, 741-746	2.7	10
61	Donor PAI-1 expression inhibits the intimal response of early allograft vascular disease. *Journal of Heart and Lung Transplantation*, **2003**, 22, 515-8	5.8	10
60	Risk stratification in pulmonary arterial hypertension using Bayesian analysis. *European Respiratory Journal*, **2020**, 56,	13.6	9
59	Association between cytokines and functional, hemodynamic parameters, and clinical outcomes in pulmonary arterial hypertension. *Pulmonary Circulation*, **2018**, 8, 2045894018794051	2.7	9
58	Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration. *Annals of the American Thoracic Society*, **2015**, 12, 269-73	4.7	8
57	The impact of delayed treatment on 6-minute walk distance test in patients with pulmonary arterial hypertension: A meta-analysis. *International Journal of Cardiology*, **2018**, 254, 299-301	3.2	8
56	Hemodynamic ranges during daily activities and exercise testing in patients with pulmonary arterial hypertension. *Journal of Cardiac Failure*, **2014**, 20, 485-91	3.3	8
55	Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension. *Pulmonary Circulation*, **2013**, 3, 116-20	2.7	8

54	Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension. *Pulmonary Circulation*, **2017**, 7, 539-542	2.7	7
53	Genetic Admixture and Survival in Diverse Populations with Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 1407-1415	10.2	7
52	Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL. *Journal of Heart and Lung Transplantation*, **2018**, 37, 948-955	5.8	7
51	Bosentan-based, treat-to-target therapy in patients with pulmonary arterial hypertension: results from the COMPASS-3 study. *Pulmonary Circulation*, **2018**, 8, 2045893217741480	2.7	7
50	Plasma levels of S100A4 in portopulmonary hypertension. *Biomarkers*, **2009**, 14, 156-60	2.6	7
49	Alterations in the fibrinolytic cascade post-transplant: evidence of a bimodal expression pattern. *Journal of Heart and Lung Transplantation*, **2007**, 26, 494-7	5.8	7
48	sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension. *Respiratory Medicine*, **2017**, 122 Suppl 1, S28-S34	4.6	6
47	Pulmonary hypertension in potential heart transplant recipients: current treatment strategies. *Current Opinion in Organ Transplantation*, **2015**, 20, 570-6	2.5	6
46	Pulmonary hypertension: chapters of innovation and tribulation. *European Heart Journal*, **2012**, 33, 961-8	9.5	6
45	Hypertriglyceridemic VLDL downregulates tissue plasminogen activator gene transcription through cis-repressive region(s) in the tissue plasminogen activator promoter in cultured human endothelial cells. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2000**, 20, 1675-81	9.4	6
44	Risk Assessment in Pulmonary Arterial Hypertension Patients: The Long and Short of it. *Advances in Pulmonary Hypertension*, **2018**, 16, 125-135	0.5	6
43	Hemodynamic response to treatment of iron deficiency anemia in pulmonary arterial hypertension: longitudinal insights from an implantable hemodynamic monitor. *Pulmonary Circulation*, **2016**, 6, 616-618	2.7	6
42	Idiopathic Pulmonary Arterial Hypertension: Evolving Therapeutic Strategies. *Seminars in Respiratory and Critical Care Medicine*, **2017**, 38, 606-618	3.9	5
41	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. *Circulation: Cardiovascular Quality and Outcomes*, **2019**, 12, e005095	5.8	5
40	United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications. *Pulmonary Circulation*, **2019**, 9, 2045894019851696	2.7	5
39	Successful treatment of acute left ventricular assist device thrombosis and cardiogenic shock with intraventricular thrombolysis and a tandem heart. *ASAIO Journal*, **2015**, 61, 98-101	3.6	5
38	Aortic graft transplantation in mice. *Journal of Heart and Lung Transplantation*, **2002**, 21, 1319-21	5.8	5
37	Does Late Gadolinium Enhancement still have Value? Right Ventricular Internal Mechanical Work, E/E and Late Gadolinium Enhancement as Prognostic Markers in Patients with Advanced Pulmonary Hypertension via Cardiac MRI **2017**, 2017,		5

36	Ethanol-Induced Up-Regulation of Candidate Plasminogen Receptor Annexin II in Cultured Human Endothelial Cells **2000**, 24, 754		5
35	In situ expression of Bcl-2 in pulmonary artery endothelial cells associates with pulmonary arterial hypertension relative to heart failure with preserved ejection fraction. *Pulmonary Circulation*, **2016**, 6, 551-556	2.7	5
34	Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: Baseline results from the Pulmonary Hypertension Association Registry. *Journal of Heart and Lung Transplantation*, **2020**, 39, 945-953	5.8	4
33	Clinical Experience of HeartMate II to HeartWare Left Ventricular Assist Device Exchange: A Multicenter Experience. *Annals of Thoracic Surgery*, **2019**, 108, 1178-1182	2.7	4
32	Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry. *Annals of the American Thoracic Society*, **2021**, 18, 613-622	4.7	4
31	In vivo Endocrine Secretion of Prostacyclin Following Expression of a Cyclooxygenase-1/Prostacyclin Fusion Protein in the Salivary Glands of Rats Via Nonviral Gene Therapy. *Human Gene Therapy*, **2017**, 28, 681-689	4.8	3
30	Management of pulmonary hypertension due to heart failure with preserved ejection fraction. *Current Hypertension Reports*, **2014**, 16, 501	4.7	3
29	Macitentan (Opsumit) for the treatment of pulmonary arterial hypertension. *Expert Review of Clinical Pharmacology*, **2014**, 7, 415-21	3.8	3
28	Identification of a BamHI Polymorphism for the Urokinase Gene Associated with Symptomatic Coronary Artery Disease. *Journal of Thrombosis and Thrombolysis*, **1998**, 5, 113-118	5.1	3
27	Risk Assessment in Patients with a Left Ventricular Assist Device Across INTERMACS Profiles Using Bayesian Analysis. *ASAIO Journal*, **2019**, 65, 436-441	3.6	3
26	Spontaneous microbubbles in the aortic root and thrombosis of a continuous-flow left ventricular assist device. *Journal of Heart and Lung Transplantation*, **2014**, 33, 550-1	5.8	2
25	Pulmonary hypertension. *Heart Failure Clinics*, **2012**, 8, xxi-xxii	3.3	2
24	Concomitant cat scratch disease and squamous cell carcinoma in a cardiac transplant. *Gastroenterology Insights*, **2012**, 4, 2	2.1	2
23	The role of fibrinolytic genes and proteins in the development of allograft vascular disease. *Journal of Heart and Lung Transplantation*, **2011**, 30, 935-44	5.8	2
22	REVEAL REGISTRY: BASELINE CHARACTERISTICS OF THE FIRST 1,226 ENROLLED PATIENTS. *Chest*, **2007**, 132, 473B	5.3	2
21	Commentary: non-immunologic vascular failure of the transplanted heart. *Journal of Heart and Lung Transplantation*, **2003**, 22, 241-3	5.8	2
20	Ambulatory Hemodynamic Monitoring in the Management of Pulmonary Arterial Hypertension. *Advances in Pulmonary Hypertension*, **2014**, 13, 81-85	0.5	2
19	Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study. *Pulmonary Circulation*, **2020**, 10, 2045894020973124	2.7	2

18	Risk assessment in patients with pulmonary arterial hypertension in the era of COVID 19 pandemic and the telehealth revolution: State of the art review. *Journal of Heart and Lung Transplantation*, **2021**, 40, 172-182	5.8	2
17	Application of the REVEAL risk score calculator 2.0 in the PATENT study. *International Journal of Cardiology*, **2021**, 332, 189-192	3.2	2
16	Integrated use of cardiac MRI and the CardioMEMS HF system in PAH: the utility of coincident pressure and volume in RV failure-the NHLBI-VITA trial. *Cardiovascular Diagnosis and Therapy*, **2019**, 9, 492-501	2.6	2
15	Use of an implantable wireless pulmonary pressure monitor during transition of therapy in pulmonary arterial hypertension. *Journal of Heart and Lung Transplantation*, **2019**, 38, 227-230	5.8	2
14	PPAR increases HUWE1 to attenuate NF-B/p65 and sickle cell disease with pulmonary hypertension. *Blood Advances*, **2021**, 5, 399-413	7.8	2
13	Aggressive Afterload Lowering to Improve the RV: A New Target for Medical Therapy in PAH?. *American Journal of Respiratory and Critical Care Medicine*, **2021**,	10.2	2
12	Residence at moderately high altitude and its relationship with WHO Group 1 pulmonary arterial hypertension symptom severity and clinical characteristics: the Pulmonary Hypertension Association Registry. *Pulmonary Circulation*, **2020**, 10, 2045894020964342	2.7	1
11	The United States Chronic Thromboembolic Pulmonary Hypertension Registry: Protocol for a Prospective, Longitudinal Study. *JMIR Research Protocols*, **2021**, 10, e25397	2	1
10	Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop. *Circulation: Heart Failure*, **2021**, 14,	7.6	1
9	EXPRESS: Switching to riociguat: A potential treatment strategy for the management of CTEPH and PAH. *Pulmonary Circulation*, **2019**, 2045894019837849	2.7	1
8	Safety and efficacy of ibutilide in heart transplant recipients. *Journal of Heart and Lung Transplantation*, **2009**, 28, 505-7	5.8	0
7	Transmyocardial and percutaneous myocardial revascularization: current concepts and future directions. *Journal of Heart and Lung Transplantation*, **2003**, 22, 837-42	5.8	0
6	Assessing hemodynamic response to submaximal exercise in pulmonary arterial hypertension patients using an implantable hemodynamic monitor. *Journal of Heart and Lung Transplantation*, **2021**, 40, 430-434	5.8	0
5	Concomitant cat scratch disease and squamous cell carcinoma in a cardiac transplant. *Gastroenterology Insights*, **2012**, 4, e2	2.1	
4	Response. *Chest*, **2018**, 154, 1262-1264	5.3	
3	The Evolution of Risk Assessment in Pulmonary Arterial Hypertension. *Methodist DeBakey Cardiovascular Journal*, **2021**, 17, 134-144	2.1	
2	Application of the REVEAL risk score calculator 2.0 in the CHEST study.. *Respiratory Medicine*, **2022**, 195, 106783	4.6	
1	Maternal and fetal outcomes in pregnant women with pulmonary hypertension: The impact of left heart disease. *International Journal of Cardiology Congenital Heart Disease*, **2022**, 8, 100354	0.7	